Novel therapies for hemodialysis vascular access dysfunction: fact or fiction!

Area of Science:

• Nephrology
• Vascular Surgery
• Cardiovascular Research

Background:

• Hemodialysis vascular access dysfunction significantly impacts patient morbidity and healthcare costs.
• Venous stenosis and thrombosis, driven by neointimal hyperplasia, are primary histological causes in both native arteriovenous fistulae and PTFE grafts.
• Current therapeutic strategies effective in coronary artery disease have not translated to hemodialysis access dysfunction.

Purpose of the Study:

• To highlight the unmet need for effective treatments for hemodialysis vascular access dysfunction.
• To identify neointimal hyperplasia in hemodialysis access as a critical area for therapeutic intervention development.
• To underscore the potential of hemodialysis vascular access as a clinical model for testing novel anti-hyperplasia therapies.

Main Methods:

• Review of existing literature on hemodialysis vascular access dysfunction.
• Histological analysis of dysfunctional vascular access (native fistulae and PTFE grafts).
• Comparison of therapeutic approaches for neointimal hyperplasia in coronary vs. hemodialysis settings.

Main Results:

• Neointimal hyperplasia is the predominant pathological finding in hemodialysis vascular access dysfunction.
• No current effective therapeutic interventions exist specifically for hemodialysis vascular access neointimal hyperplasia.
• Significant data exists for neointimal hyperplasia interventions in coronary artery disease.

Conclusions:

• Hemodialysis vascular access dysfunction, primarily due to neointimal hyperplasia, remains a major clinical challenge.
• The lack of effective treatments necessitates further research and development.
• Hemodialysis vascular access provides a valuable clinical platform for evaluating novel anti-neointimal hyperplasia strategies.